Luke Miels
Chief Executive Officer
2026 – Present
0 years (current)
Key Decisions & Impact
Assuming the role of CEO in early 2026 after serving as Chief Commercial Officer, Luke Miels immediately initiated a comprehensive strategic review aimed at maximizing the value of the company's newly focused biopharma portfolio. He implemented a rigorous operational restructuring program, deliberately reallocating substantial capital away from mature, declining product lines and directing those funds toward accelerating late-stage clinical trials in the crucial oncology and immunology pipelines. Furthermore, he heavily prioritized the integration of artificial intelligence into the drug discovery process to shorten development timelines.
Legacy
Miels represents the execution phase of GSK's decade-long corporate transformation. With the consumer healthcare business officially separated, his leadership is focused on proving that the remaining pure-play biopharmaceutical company can consistently deliver innovative new medicines and generate sustainable, high-margin revenue growth. His deep commercial expertise is critical in ensuring that the company's R&D investments actually translate into successful, profitable product launches in an increasingly competitive global pricing environment.